A new study offers fresh insight into Alzheimer’s disease by looking beyond the brain and focusing on metabolic health, particularly obesity.

 

The Houston Methodist-led study moves beyond the traditional view of obesity as a general health risk and investigates how obesity-related changes in body fat can send harmful signals to the brain, disrupting brain immune function, thereby worsening Alzheimer’s pathology. Co-led by Stephen Wong, Ph.D., the John S. Dunn Presidential Distinguished Chair in Biomedical Engineering and Li Yang, Ph.D., research associate in the Chao Center for BRAIN at Houston Methodist, the study appears in Molecular Neurodegeneration.

 

The research identified phosphatidylethanolamines (PEs), a specific type of fat molecule, as a key link between obesity and Alzheimer’s disease. Researchers found that obesity increases the levels of this fat molecule in body tissue, where it is packaged into tiny particles and carried to the brain. Once there, the particles disrupt brain cell communication, weaken immune defenses and promote the buildup of amyloid proteins—hallmarks of Alzheimer’s disease.

 

 “Obesity can change how signals travel to the brain,” Wong said. “The good news is that this may be something we can treat. Instead of looking at Alzheimer's risk tied to obesity as just a metabolic problem, this research suggests we may be able to target the process that connects those changes to the brain.”

 

The study also points to a possible therapeutic direction. The team found that restoring balance in PEs reduced lipid dysregulation, improved brain function and improved cognitive performance in Alzheimer’s disease models.

 

According to the Centers for Disease Control and Prevention, more than 6.5 million Americans are living with Alzheimer's, a number projected to reach nearly 14 million by 2060.

 

Yang said while additional studies are needed to translate PE-targeted interventions into human prevention or treatment strategies, the work opens a new path for early intervention in people with metabolic risk for Alzheimer’s disease.

 

Other collaborators on the study include Li Yang, Jianting Sheng, Shaohua Qi, Zheng Yin, Michael Chan, Yuliang Cao, Hong Zhao, Zhihao Wan, Bill Chan, Ju Ahn, Xiaohui Yu, Matthew Vasquez and Shan Xu from Houston Methodist; Xianlin Han from the University of Texas, San Antonio; Weiming Xia from Boston University and Willa Hsueh from Ohio State University.

 

The study was funded by grants from the Cure Alzheimer’s Fund, the T.T. and W.F. Chao Foundation, and the John S. Dunn Research Foundation.